Compare Ascendis Pharma A/S (ASND) vs Eaton Corporation plc (ETN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Eaton Corporation plc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Eaton Corporation plc trades at $404.7 (market cap $158.15B). The key difference: Eaton Corporation plc is far larger — about 8.9× Ascendis Pharma A/S's market cap, and Eaton Corporation plc pays a 1.08% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ETN | |
|---|---|---|
Market Cap | $17.74B | $158.15B |
Sector | Health | Technology |
52-Week High | $277.18 | $435.78 |
52-Week Low | $163.32 | $315.82 |
Enterprise Value | $18.11B | $179.23B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Eaton (ETN) trades at $407.28, up 0.36% today, with a neutral technical stance and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.81 surpassing the $2.73 estimate. Fundamentals remain robust with a 36.89% gross margin and 20.87% ROE, though valuation multiples like the 39.85 P/E are elevated. Recent news highlights expansion in energy infrastructure and sustainability investments.
Outlook is positive given analyst consensus targets near $449.50 and zero sell ratings, but risks include high valuation sensitivity and projected 2026 cash flow pressure from increased investing activity. The stock offers growth exposure to power management and AI infrastructure trends, balanced by execution risks in a competitive industrial sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
